secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cidara Therapeutics, Inc. (—)
CIK:        0001610618
Form:       8-K
Filed at:   2024-04-24T23:59:59+00:00
Accession:  0001610618-24-000050
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Cidara sells rezafungin assets to NAPP/Mundipharma; debt forgiveness and milestone payment
--------------------------------------------------------------------------------

- Sold all rezafungin acetate assets to NAPP Pharmaceutical Group Ltd, effective April 24, 2024.
- Mundipharma forgave $11.145M development milestone advance due Dec 31, 2024, subject to conditions.
- Received $2.786M milestone from Mundipharma for UK approval of rezafungin for invasive candidiasis.
- Cidara agrees to 7-year non-compete for echinocandin antifungal products; exceptions if acquired.
- Melinta license amended and novated to NAPP; Cidara provides transition services for 45-75 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610618/000161061824000050/0001610618-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610618/000161061824000050/cdtx-20240423.htm
  HTML page:      https://secwatch.observer/filing/0001610618-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer